Case-Based Learning: Maternal Tachycardia With Normal Structural Heart Findings

Abstract

Maternal tachycardia, defined as a sustained heart rate exceeding 100 beats per minute in pregnancy, is a relatively common clinical scenario that frequently prompts evaluation. When structural cardiac abnormalities are absent, the differential diagnosis spans physiological adaptations, arrhythmias, and secondary causes such as endocrine disorders. This review synthesizes current evidence on the epidemiology, pathophysiology, risk factors, clinical features, diagnostic approach, and management of tachycardia in pregnant patients with structurally normal hearts. Emphasis is placed on integrating case-based learning with guideline-driven strategies, highlighting recent advances and clinical pearls relevant for practicing clinicians.

Introduction

Cardiovascular changes in pregnancy are profound, leading to an increase in blood volume, cardiac output, and heart rate. While mild tachycardia may be a physiological response, persistent or symptomatic tachycardia warrants careful evaluation to differentiate benign from pathologic etiologies. In the absence of structural heart disease, clinicians must systematically approach maternal tachycardia to identify reversible causes, ensure maternal and fetal safety, and optimize outcomes. This article reviews the literature and guidelines to provide a structured framework for the assessment and management of maternal tachycardia with normal structural heart findings.

Epidemiology / Disease Burden

Tachycardia is observed in up to 10-15% of pregnancies, with most cases attributable to physiological adaptation. However, inappropriate sinus tachycardia (IST), supraventricular tachycardias (SVT), and secondary causes such as anemia or hyperthyroidism represent significant contributors to symptomatic presentations. Recent population-based studies indicate that arrhythmias, though less common than hypertensive or thromboembolic events, are an important cause of maternal morbidity. Notably, the prevalence of SVT in pregnancy is estimated at 22-25 per 100,000 pregnancies, with the majority occurring in structurally normal hearts.

Pathophysiology

During pregnancy, increased sympathetic tone, elevated circulating catecholamines, and hormonal fluctuations collectively augment heart rate. The expansion in plasma volume and reduction in systemic vascular resistance increase cardiac output, often manifesting as a resting tachycardia. In the absence of structural heart disease, mechanisms underlying pathological tachycardia include enhanced automaticity, triggered activity, or reentrant circuits within the atria or AV node. IST is believed to involve abnormal autonomic regulation, while SVT commonly arises from reentrant pathways such as AV nodal reentrant tachycardia (AVNRT) or AV reentrant tachycardia (AVRT). Thyrotoxicosis, anemia, infection, and drug effects may further exacerbate tachycardia via direct or indirect myocardial stimulation.

Risk Factors

Risk factors for maternal tachycardia with normal cardiac structure encompass physiological, pathological, and iatrogenic contributors. Advanced maternal age, high parity, obesity, and pre-existing endocrine disorders (especially hyperthyroidism) increase susceptibility. Hemodynamic stressors such as anemia, dehydration, infection, and pain are frequent precipitants. Use of beta-adrenergic medications, stimulants, or illicit drugs may also provoke tachyarrhythmias. A personal or family history of arrhythmias, even in the absence of structural anomalies, can signal an underlying predisposition.

Clinical Features

Patients may present with palpitations, dizziness, exertional intolerance, chest discomfort, or anxiety. Syncope is uncommon but warrants urgent evaluation. Physical examination may reveal tachycardia, bounding pulses, and in some cases, signs of volume overload or thyrotoxicosis. Importantly, the absence of murmurs or abnormal heart sounds helps exclude structural disease. Fetal compromise is rare in isolated maternal tachycardia but should be considered in severe or sustained cases. The clinical context, including onset, triggers, and associated symptoms, guides the differential diagnosis.

Diagnosis

Evaluation should be systematic, beginning with thorough history and examination. Electrocardiography (ECG) is essential to characterize rhythm and exclude pre-excitation or conduction abnormalities. Laboratory assessment includes thyroid function tests, complete blood count, electrolyte panel, and infection markers. Echocardiography is indicated when symptoms are severe, there is suspicion of underlying disease, or initial workup is inconclusive. Ambulatory ECG monitoring may be warranted in intermittent or unexplained cases. Differential diagnosis includes IST, SVT, atrial fibrillation, and secondary causes such as metabolic or endocrine derangements. Exclusion of pulmonary embolism or sepsis is critical in acutely ill patients.

Treatment & Management

Management is tailored to etiology, severity, and gestational age. For physiological tachycardia, reassurance and non-pharmacological interventions (hydration, rest, avoidance of triggers) are often sufficient. Pathological tachycardias, such as SVT, may respond to vagal maneuvers; if ineffective and hemodynamic stability is maintained, pharmacological agents like adenosine or beta-blockers (e.g., metoprolol) are preferred, with caution regarding fetal effects. Digoxin and verapamil are alternatives if beta-blockers are contraindicated. Treatment of secondary causes (e.g., anemia, infection, hyperthyroidism) is crucial. In refractory or life-threatening cases, synchronized cardioversion is safe in pregnancy. Multidisciplinary care involving obstetrics, cardiology, and anesthesia optimizes maternal and fetal outcomes.

Recent Advances / Emerging Therapies

Recent years have seen advances in non-invasive cardiac mapping and risk stratification tools to distinguish benign from malignant arrhythmias in pregnancy. Wearable ambulatory monitors and smartphone-based ECG technologies facilitate early detection and monitoring. Catheter ablation, traditionally deferred until postpartum, is increasingly considered in selected patients with drug-refractory SVT, utilizing zero- or ultra-low-fluoroscopy techniques to minimize fetal exposure. Ongoing research into the safety of novel antiarrhythmic agents and individualized risk prediction models aims to further refine management.

Guideline Recommendations

Current guidelines from the European Society of Cardiology (ESC) and American College of Cardiology (ACC) recommend a stepwise approach: initial non-pharmacologic therapy, judicious use of medications with established fetal safety profiles, and consideration of invasive interventions only after multidisciplinary review. Regular fetal assessment is advised in cases of sustained maternal tachycardia or medication exposure. Preconception counseling and risk stratification are encouraged in women with known arrhythmia history.

Conclusion

Maternal tachycardia in the context of structurally normal cardiac anatomy presents a diagnostic and therapeutic challenge. A systematic, evidence-based approach is essential to distinguish physiological from pathological causes, ensure maternal-fetal safety, and guide intervention. Advances in diagnostic modalities and emerging therapeutics continue to enhance the armamentarium available to clinicians. Ongoing research and interdisciplinary collaboration remain pivotal to optimizing care for this unique patient population.